By VETTAPHARMA reporter – Derek Roche: Moderna reported that three abstracts featuring its investigational mRNA-based oncology programs were accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting progress in personalized cancer vaccines and hematologic malignancies.
The centerpiece of the presentation program is a five-year update from the Phase IIb KEYNOTE-942 study evaluating individualized neoantigen therapy intismeran autogene in combination with pembrolizumab in patients with resected melanoma. The oral presentation is scheduled for June 1 and will provide the longest follow-up reported to date for the personalized cancer vaccine program jointly developed by Moderna and Merck & Co..
Moderna will also present data examining the ability of intismeran autogene to induce de novo neoantigen-specific T-cell responses as adjuvant therapy in melanoma. The findings are expected to provide additional insight into the immunologic mechanisms underlying the personalized mRNA therapeutic approach.
A third presentation will feature a Phase I/II study of mRNA-2808 in patients with relapsed or refractory multiple myeloma, extending Moderna’s oncology efforts beyond solid tumors into hematologic cancers. The study is designed to evaluate the safety and clinical activity of the investigational mRNA therapeutic in heavily pretreated patients.
The ASCO presentations come as Moderna continues to diversify beyond its respiratory vaccine franchise and advance oncology programs viewed as key long-term growth drivers. Personalized cancer vaccines remain one of the most closely watched areas of cancer drug development as companies seek to leverage genomic information to generate patient-specific anti-tumor immune responses.
For patients with melanoma, long-term follow-up from KEYNOTE-942 could provide important evidence regarding the durability of benefit associated with individualized neoantigen therapy. In multiple myeloma, early clinical data may help determine the feasibility of applying mRNA-based therapeutics to hematologic malignancies.
From a commercial perspective, positive long-term melanoma data could further support advancement of Moderna’s personalized cancer vaccine platform and strengthen the company’s position in the emerging field of individualized oncology therapeutics.
Quick FAQs
1. What is intismeran autogene?
Intismeran autogene is an investigational individualized neoantigen therapy being developed by Moderna and Merck for cancer treatment.
2. What was announced by Moderna at ASCO 2026?
Moderna reported that three oncology abstracts were accepted for presentation, including updates from melanoma and multiple myeloma programs.
3. What is the KEYNOTE-942 study?
KEYNOTE-942 is a clinical study evaluating intismeran autogene plus pembrolizumab in patients with resected melanoma.
4. What is melanoma?
Melanoma is a form of skin cancer that develops from pigment-producing melanocytes and can become life-threatening if it spreads.
5. What is mRNA-2808 being studied for?
mRNA-2808 is being evaluated in a Phase I/II study involving patients with relapsed or refractory multiple myeloma.
6. Why are these ASCO presentations important?
The presentations provide updates on Moderna’s oncology pipeline, a strategic area of growth beyond vaccines.
